<div id="readability-page-1"><p>Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average rating of &#34;Moderate Buy&#34; by the ten analysts that are currently  covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one  has assigned  a hold recommendation and seven have issued  a buy recommendation on  the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.00.</p><ul><li>MarketBeat Week in Review – 11/4 - 11/8</li></ul><p>ALT has been the topic of several recent analyst reports. Truist Financial initiated coverage on shares of Altimmune in a research report on Wednesday, March 18th. They set a &#34;buy&#34; rating and a $12.00 target price on the stock. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Altimmune in a research report on Friday, March 27th. HC Wainwright upped their target price on shares of Altimmune from $12.00 to $25.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, March 16th. William Blair  restated a &#34;market perform&#34; rating on shares of Altimmune in a research report on Thursday, March 5th. Finally, B. Riley Financial lowered their target price on shares of Altimmune from $18.00 to $13.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, March 6th.</p><p><b>Get Our Latest Report on Altimmune</b></p><h2>Altimmune Trading Down 0.2%</h2><ul><li>How Altimmune Could Grab a Big Chunk of the GLP-1 Market</li></ul><p>Shares of ALT opened at $2.85 on Monday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. The firm's 50-day moving average is $3.64 and its two-hundred day moving average is $4.19. Altimmune has a twelve month low of $2.80 and a twelve month high of $7.73. The firm has a market capitalization of $370.13 million, a P/E ratio of -2.82 and a beta of 0.34. </p><p>Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million.  On average, research analysts predict that  Altimmune will post -1 earnings per share for the current fiscal year. </p><h2>Insider Activity at Altimmune</h2><ul><li>This Small Cap Wealth Management Stock Could Provide Big Returns</li></ul><p>In other Altimmune news, CEO Jerome Benedict Durso purchased 20,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer directly owned 32,500 shares of the company's stock, valued at $115,050. This trade represents a 160.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders. </p><h2>Institutional Trading of Altimmune</h2><p>Large investors have recently modified their holdings of the business. Arax Advisory Partners grew its position in shares of  Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company's stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter.  SBI Securities Co. Ltd. grew its position in shares of  Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company's stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter.  Quadrature Capital Ltd acquired a new stake in shares of  Altimmune in the fourth quarter valued at approximately $36,000.  Victory Capital Management Inc. acquired a new stake in shares of  Altimmune in the third quarter valued at approximately $38,000.  Finally, CreativeOne Wealth LLC acquired a new stake in shares of  Altimmune in the fourth quarter valued at approximately $38,000. 78.05% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Altimmune</h2> (Get Free Report)<p>Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.  </p><p>Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.</p><h2>Read More</h2><ul><li>Five stocks we like better than Altimmune</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxU"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Altimmune Right Now?</h2><p>Before you consider Altimmune, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.</p><p>While Altimmune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

ARKG

<p>Altimmune, Inc. (NASDAQ:ALT) has received an average analyst rating of "Moderate Buy" from ten analysts. The stock has two sell ratings, one hold, and seven buy recommendations. The average 12-month price target is $18.00. Recent analyst reports include a buy rating from Truist Financial with a $12.00 target, and HC Wainwright raised their target from $12.00 to $25.00. CEO Jerome Durso purchased 20,000 shares at $3.54 each, increasing his ownership by 160%. Altimmune focuses on developing vaccines and immunotherapeutics for various diseases.</p>

Market Beat

Altimmune

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

VG Health

iShares Biotechnology ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Truist Financial

SBI Holdings, Inc.

Victory

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts